Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 986 PK in severe renal impairment
NCT03318809Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azelaprag in heart failure (HF) (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample at 120 hours, Maximum Observed Plasma Concentration After Dosing at 120 hours and 3 more. Started Dec 2017; status: completed.
02
Drugs
azelaprag
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03318809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318809.